SSA
KPTI icon

Schonfeld Strategic Advisors’s Karyopharm Therapeutics KPTI Stock Holding History

Schonfeld Strategic Advisors’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-3,840
Closed -$50K – 2230
2024
Q2 		$50K Buy
+3,840
New +$63.6K ﹤0.01% 1932
2022
Q4 		– Sell
-1,257
Closed -$102K – 2821
2022
Q3 		$102K Buy
+1,257
New +$93.9K ﹤0.01% 2541
2021
Q4 		– Sell
-1,174
Closed -$102K – 2348
2021
Q3 		$102K Buy
+1,174
New +$122K ﹤0.01% 1919
2021
Q2 		– Sell
-11,914
Closed -$1.88M – 2125
2021
Q1 		$1.88M Buy
+11,914
New +$2.51M 0.02% 680
2020
Q3 		– Sell
-1,423
Closed -$405K – 1515
2020
Q2 		$405K Buy
1,423
+421
+42% +$125K 0.01% 883
2020
Q1 		$289K Sell
1,002
-4,802
-83% -$1.32M 0.02% 771
2019
Q4 		$1.67M Sell
5,804
-13,203
-69% -$2.86M 0.04% 374
2019
Q3 		$2.74M Buy
+19,007
New +$2.58M 0.08% 255
2019
Q2 		– Sell
-6,987
Closed -$612K – 1129
2019
Q1 		$612K Sell
6,987
-1,200
-15% -$133K 0.02% 637
2018
Q4 		$1.15M Sell
8,187
-19,686
-71% -$3.32M 0.04% 444
2018
Q3 		$7.12M Buy
27,873
+166
+0.6% +$45.9K 0.32% 82
2018
Q2 		$7.06M Buy
27,707
+3,514
+15% +$869K 0.38% 69
2018
Q1 		$4.87M Buy
24,193
+7,526
+45% +$1.5M 0.37% 70
2017
Q4 		$2.4M Hold
16,667
– – 0.2% 145
2017
Q3 		$2.75M Sell
16,667
-5,000
-23% -$716K 0.25% 124
2017
Q2 		$2.94M Sell
21,667
-1,000
-4% -$148K 0.3% 92
2017
Q1 		$4.37M Buy
+22,667
New +$3.64M 0.44% 56

Other funds holding KPTI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Schonfeld Strategic Advisors's KPTI Position: Q3 2024 in Review

Schonfeld Strategic Advisors sold out of Karyopharm Therapeutics (KPTI) in Q3 2024, closing a stake of 3,840 shares — an estimated $50K sold.

Schonfeld Strategic Advisors first reported a position in KPTI in Q1 2017 and held it in 17 quarters. The position peaked at $7.12M in Q3 2018. 91 funds tracked by Wall St. Rank hold KPTI as of Q3 2024.

  • Schonfeld Strategic Advisors reported no remaining Karyopharm Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 3,840 Karyopharm Therapeutics shares in Q3 2024, an estimated $50K.
  • Schonfeld Strategic Advisors first reported a position in Karyopharm Therapeutics in Q1 2017 and held it in 17 quarters.
  • Schonfeld Strategic Advisors's Karyopharm Therapeutics position peaked at $7.12M in Q3 2018.
  • 91 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2024.

Based on Schonfeld Strategic Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.